Table 2.
Data extraction form
| Questions | Possible categories |
|---|---|
| Subject area | |
| What is the study’s subject area? | Cardiology, Oncology, Psychiatry, Neurology, etc. |
| Data type | |
| Were EHRs or EMRs data used? | Yes or no. |
| If not, what type of data were used? | Cohort study data, Patient registry data, etc. |
| Specify the name of the observational database. | Free text. |
| Data structure | |
| Were structured data used? | Yes or no. |
| Were unstructured data used? | Yes or no. |
| If unstructured data were used, were these manually or automatically processed? | Manually or automatically. |
| Eligibility criteria | |
| What is the target population? | Free text. |
| Treatments | |
| How many treatments were compared? | Number of treatments. |
| What treatments were compared? | Free text. |
| Outcomes | |
| What was(were) the primary outcome(s)? | Free text. |
| Follow-up | |
| Was the follow-up duration pre-specified? | Yes or no. |
| Statistical objectives | |
| What is the estimand of interest? | Causal effect of point treatment offer (‘intention-to-treat effect’), causal effect of point treatment receipt (‘per-protocol effect’), causal effect of treatment regimen initiation (‘intention-to-treat effect’) or causal effect of sustained treatment regimen (‘per-protocol effect’). |
| What was the measurement scale of the outcome(s)? | Continuous, ordinal, binary, time-to-event, other. |
| Which effect size measure was used to quantify the causal contrast of interest? | Mean difference, odds ratio, hazard ratio, other. |
| Which statistical method was used for analysing the primary outcome(s)? | Pooled logistic regression, Cox proportional hazards model, etc. |
| Were sample size or statistical power calculations provided? | Yes or no. |
| If yes, what was determined? | Power or the effect size. |
| Treatment assignment procedures | |
| Were treatments administered at one point in time or sustained over time? | Point treatment or treatment regimen. |
| In either case have pre-initiation confounders been adjusted for? | Yes or no. |
| If the answer to the last question is ‘yes’, what statistical method has been used for this purpose? | Inclusion of covariates in model, stratification, inverse probability of treatment weighting, propensity score methods, parametric g-formula, other, method not specified. |
| If treatment regimen, are the investigators interested in the effect of initiating a treatment or the effect of sustaining a treatment? | Initiation or sustained treatment. |
| If interested in the effect of a sustained treatment, did they account for time-varying confounders? | Yes or no. |
| If the answer to the last question is ‘yes’, what statistical method has been used for this purpose? | Inverse probability of treatment weighting, parametric g-formula, other, method not specified. |
| Other bias handling | |
| Was immortal-time bias addressed? | Yes or no. |
| If yes, how was immortal-time bias handled? | Avoided at the study design stage or using the cloning technique. |
| Was selection bias due to loss to follow-up addressed explicitly? | Yes or no. |
| If so, how were missing outcome data handled? | Inverse probability of censoring weighting, multiple imputation, etc. |
Abbreviations: EHRs Electronic Health Records, EMRs Electronic Medical Records